Christina E. Nixon

Christina E. Nixon

Auto-generated profile, based on publicly available information

Christina E. Nixon

Center for International Health Research, Rhode Island Hospital, Providence, RI 2

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2014 in Science
Verified
Journal Article
Closed access
PDF file
DRDipak K. Raj
Dipak K. Raj
CNChristian P. Nixon
Christian P. Nixon
CNChristina E. Nixon
Christina E. Nixon
JDJeffrey D. Dvorin
Jeffrey D. Dvorin
CDChristen G. DiPetrillo
Christen G. DiPetrillo
JKJonathan D. Kurtis
Jonathan D. Kurtis
Novel vaccines are urgently needed to reduce the burden of severe malaria. Using a differential whole-proteome screening method, we identified Plasmodium falciparum schizont egress antigen-1 (PfSEA-1), a 244-kilodalton parasite antigen expressed in schizont-infected red blood cells (RBCs). Antibodies to PfSEA-1 decreased parasite replication by arresting schizont rupture, and conditional disruption of PfSEA-1 resulted in a profound parasite replication defect. Vaccination of mice with recombinant Plasmodium berghei PbSEA-1 significantly reduced parasitemia and delayed mortality after lethal challenge with the Plasmodium berghei strain ANKA. Tanzanian children with antibodies to recombinant PfSEA-1A (rPfSEA-1A) did not experience severe malaria, and Kenyan adolescents and adults with antibodies to rPfSEA-1A had significantly lower parasite densities than individuals without these antibodies. By blocking schizont egress, PfSEA-1 may synergize with other vaccines targeting hepatocyte and RBC invasion.

15 May 2018 in Blood Advances
Verified
Journal Article
Closed access
PDF file
CFCatherine Forconi
Catherine Forconi
CCCormac P. Cosgrove
Cormac P. Cosgrove
PSPryia Saikumar-Lakshmi
Pryia Saikumar-Lakshmi
CNChristina E. Nixon
Christina E. Nixon
JFJoslyn Foley
Joslyn Foley
AMAnn Moormann
Ann Moormann
Natural killer (NK) cells are critical for restricting viral infections and mediating tumor immunosurveillance. Epstein-Barr virus (EBV) and Plasmodium falciparum malaria are known risk factors for endemic Burkitt lymphoma (eBL), the most common childhood cancer in equatorial Africa. To date, the composition and function of NK cells have not been evaluated in eBL etiology or pathogenesis. Therefore, using multiparameter flow cytometry and in vitro killing assays, we compared NK cells from healthy children and children diagnosed with eBL in Kenya. We defined 5 subsets based on CD56 and CD16 expression, including CD56negCD16pos. We found that licensed and terminally differentiated perforin-expressing CD56negCD16pos NK cells accumulated in eBL children, particularly in those with high EBV loads (45.2%) compared with healthy children without (6.07%) or with (13.5%) malaria exposure (P = .0007 and .002, respectively). This progressive shift in NK cell proportions was concomitant with fewer CD56dimCD16pos cells. Despite high MIP-1β expression, CD56negCD16pos NK cells had diminished cytotoxicity, with lower expression of activation markers NKp46, NKp30, and CD160 and the absence of TNF-α. Of note, the accumulation of poorly cytotoxic CD56negCD16pos NK cells resolved in long-term eBL survivors. Our study demonstrates impaired NK cell–mediated immunosurveillance in eBL patients but with the potential to restore a protective NK cell repertoire after cancer treatment. Characterizing NK cell dysfunction during coinfections with malaria and EBV has important implications for designing immunotherapies to improve outcomes for children diagnosed with eBL. Key Points Terminally differentiated CD56neg NK cells expand in children after chronic malaria exposure and in those diagnosed with eBL. NK cells in eBL patients express high levels of MIP-1β in lieu of TNF-α, and normal NK cell profiles appear to be restored in eBL survivors. Visual Abstract

10 April 2019 in Parasite Immunology
Verified
Journal Article
Closed access
PDF file
AMAnn Moormann
Ann Moormann
CNChristina E. Nixon
Christina E. Nixon
CFCatherine Forconi
Catherine Forconi

10 December 2014 in Pathogens and Global Health
Verified
Journal Article
Closed access
CNChristian P. Nixon
Christian P. Nixon
CNChristina E. Nixon
Christina E. Nixon
Dian Sidik ArsyadDian Sidik Arsyad
Dian Sidik Arsyad
KCKrisin Chand
Krisin Chand
FYFrilasita A. Yudhaputri
Frilasita A. Yudhaputri
JBJ. Kevin Baird
J. Kevin Baird
The decline in intensity of malaria transmission in many areas now emphasizes greater importance of understanding the epidemiology of low to moderate transmission settings. Marked heterogeneity in infection risk within these populations creates opportunities to understand transmission and guide resource allocation to greater impact. In this study, we examined spatial patterns of malaria transmission in a hypo- to meso-endemic area of eastern Indonesia using malaria prevalence data collected from a cross-sectional socio-demographic and parasitological survey conducted from August to November 2010. An entomological survey performed in parallel, identified, mapped, and monitored local anopheline larval habitats. A single spatial cluster of higher malaria prevalence was detected during the study period (relative risk=2.13; log likelihood ratio=20.7; P<0.001). In hierarchical multivariate regression models, risk of parasitemia was inversely correlated with distance to five Anopheles sundaicus known larval habitats [odds ratio (OR)=0.21; 95% confidence interval (CI)=0.14-0.32; P<0.001], which were located in a geographically restricted band adjacent to the coastline. Increasing distance from these sites predicted increased hemoglobin level across age strata after adjusting for confounders (OR=1.6; 95% CI=1.30-1.98; P<0.001). Significant clustering of malaria parasitemia in close proximity to very specific and relatively few An. sundaicus larval habitats has direct implications for local control strategy, policy, and practice. These findings suggest that larval source management could achieve profound if not complete impact in this region.

25 August 2018 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
JKJonathan D Kurtis
Jonathan D Kurtis
DRDipak K Raj
Dipak K Raj
IMIan C Michelow
Ian C Michelow
SPSangshin Park
Sangshin Park
CNChristina E Nixon
Christina E Nixon
MFMichal Fried
Michal Fried
Background: In holoendemic areas, children suffer the most from Plasmodium falciparum malaria, yet newborns and young infants express a relative resistance to both infection and severe malarial disease (SM). This relative resistance has been ascribed to maternally-derived anti-parasite immunoglobulin G; however, the targets of these protective antibodies remain elusive.Methods: We enrolled 647 newborns at birth from a malaria-holoendemic region of Tanzania. We collected cord blood, measured antibodies to Plasmodium falciparum Schizont Egress Antigen-1 (PfSEA-1), and related these antibodies to the risk of severe malaria in the first year of life. In addition, we vaccinated female mice with PbSEA-1, mated them, and challenged their pups with P. berghei ANKA parasites to assess the impact of maternal PbSEA-1 vaccination on newborns’ resistance to malaria.Results: Children with high cord-blood anti–PfSEA-1 antibody levels had 51.4% fewer cases of SM compared to individuals with lower anti–PfSEA-1 levels over 12 months of follow-up (P = .03). In 3 trials, pups born to PbSEA-1–vaccinated dams had significantly lower parasitemia and longer survival following a P. berghei challenge compared to pups born to control dams.Conclusions: We demonstrate that maternally-derived, cord-blood anti–PfSEA-1 antibodies predict decreased risk of SM in infants and vaccination of mice with PbSEA-1 prior to pregnancy protects their offspring from lethal P. berghei challenge. These results identify, for the first time, a parasite-specific target of maternal antibodies that protect infants from SM and suggest that vaccination of pregnant women with PfSEA-1 may afford a survival advantage to their offspring.

1 July 2017 in Clinical and Vaccine Immunology
Verified
Journal Article
Closed access
PDF file
CNChristina E. Nixon
Christina E. Nixon
SPSangshin Park
Sangshin Park
SPSunthorn Pond-Tor
Sunthorn Pond-Tor
DRDipak Raj
Dipak Raj
LLLynn E. Lambert
Lynn E. Lambert
JKJonathan D. Kurtis
Jonathan D. Kurtis
Naturally acquired antibodies to Plasmodium falciparum schizont egress antigen 1 (PfSEA-1A) are associated with protection against severe malaria in children. Vaccination of mice with SEA-1A from Plasmodium berghei (PbSEA-1A) decreases parasitemia and prolongs survival following P. berghei ANKA challenge. To enhance the immunogenicity of PfSEA-1A, we identified five linear B-cell epitopes using peptide microarrays probed with antisera from nonhuman primates vaccinated with recombinant PfSEA-1A (rPfSEA-1A). We evaluated the relationship between epitope-specific antibody levels and protection from parasitemia in a longitudinal treatment-reinfection cohort in western Kenya. Antibodies to three epitopes were associated with 16 to 17% decreased parasitemia over an 18-week high transmission season. We are currently designing immunogens to enhance antibody responses to these three epitopes.